retatrutide triple agonist glp-1 gip glucagon receptors UK Research Library Retatrutide for Obesity: Phase 2

[DOI] [PMC free article] [PubMed] [Google Scholar] 294.Saha P, Kathuria H, Pandey MM

So the question became: what can we add that makes that success healthier and more durable? There are many GLP1s in development, he said

Obesity care, GLP-1s and the new equation for plan sponsors GLP-1s are transforming obesity care, and the decisions plan sponsors make will impact their organizations for years to come Daniel Cusator , MD, MBA, Account Medical Director, Blue Cross Blue Shield of Tennessee Shane Lipp , Senior Benefits Manager, Synovus Claire Morrow , PT, DPT, OCS, FAAOMPT, Physical Therapy Consultant Senior Manager, Hinge Health Charlie Smith , MD, Chief Medical Officer, AON Gabrielle Boisvert , Head of Solution Strategy, Teladoc Health (Moderator) In 2021, it was the beginning of the widespread, mainstream use of GLP-1s for weight loss

Redox Signal 23 (9), 711723